Better tolerability and treatment compliance
Pritor®/Kinzal® demonstrated better tolerability and compliance to treatment than ramipril in the ONTARGET® trial, which had a patient population shown to tolerate ACE inhibitors. Fewer patients permanently discontinued Pritor®/Kinzal® treatment relative to ramipril treatment:1
